KRAS and sarcoma: To determine whether AAV/Cas9-mediated somatic HDR could be used to introduce point mutations into Kras and drive sarcoma formation, we performed intramuscular injections of AAV-KrasHDR/sgKras/Cre into the gastrocnemii of PT;H11LSL-Cas9 mice (Fig. 5a and Supplementary Fig. 8a).